Oncotelic Therapeutics (OTCQB: OTLC) announced the completion of key Phase 2 objectives in its manufacturing automation initiative with TechForce Robotics, advancing the commercialization of an AI-powered good manufacturing practices (GMP) manufacturing services platform at SAPU Bio, the company’s 45%-owned sterile injectable cGMP manufacturing joint venture.
The Phase 2 deployment expands the capabilities of Oncotelic’s proprietary PDAOAI(TM) platform across sterile manufacturing operations, electronic batch records, GMP workflow execution, cleanroom monitoring and autonomous materials movement. According to the company, the integrated platform combines PDAOAI(TM) with TechForce’s autonomous robotic systems to support intelligent pharmaceutical manufacturing and create potential opportunities in software licensing, automation deployment, manufacturing partnerships and technology-enabled contract development and manufacturing services (CDMO).
This development is significant because it demonstrates the practical application of artificial intelligence and robotics in pharmaceutical manufacturing, an area that has traditionally lagged in automation compared to other industries. By integrating AI and robotics into GMP-compliant sterile manufacturing, Oncotelic is positioning itself to offer a novel service that could reduce human error, increase efficiency, and lower costs for drug production. The platform’s ability to handle electronic batch records and cleanroom monitoring autonomously addresses key regulatory and quality control challenges in pharmaceutical manufacturing.
Oncotelic plans to demonstrate the platform at the BIO International Convention 2026 in San Diego as it pursues broader commercialization efforts within the pharmaceutical manufacturing sector. This upcoming demonstration could attract potential partners and customers, including large pharmaceutical companies looking to modernize their production facilities.
The implications of this announcement extend beyond Oncotelic itself. If successful, the PDAOAI(TM) platform could set a new standard for automated pharmaceutical manufacturing, potentially influencing industry-wide adoption of similar technologies. For investors, the development opens up multiple revenue streams: software licensing for the AI platform, automation deployment services, manufacturing partnerships, and tech-enabled CDMO services. Additionally, the platform could be licensed to other contract manufacturers or pharmaceutical companies, providing a scalable business model.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products. The company also leverages its proprietary AI-enabled PDAOAI platform for research, biomarker discovery, and regulatory processes. Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures, including a 45% interest in GMP Bio.
For more information, visit the company’s newsroom at https://nnw.fm/OTLC and the full press release at https://nnw.fm/j1n43.
